IHT is dedicated to examining, in clinical settings, the costs and benefits of alternative therapeutic approaches to advanced wound care. The comparative effectiveness evaluations are intended to demonstrate proof of value by achieving reductions in cost and establishing appropriate clinical pathways resulting in selecting products with the highest value. It is now clear that both value-based purchasing and alternative comparative product effectiveness will determine the way in which advanced wound care products are purchased and consumed. By taking an informed and responsible approach toward value-based purchasing and comparative effectiveness studies and analysis, IHT can impact patient outcomes at a reduced cost and create a favorable competitive and economic advantage for healthcare providers and payers.
- PhaseOne images
- Cutimed Sorbact images